OCUL insider buying and SEC filings, explained
Ocular Therapeutix, Inc. · CIK 1393434
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$461K
Insiders who bought
1
Sold (not marked 10b5-1)
$216K
Planned sales (10b5-1)
$3.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 8, 2026 | Planned (10b5-1) | Todd Anderman (Chief Legal Officer) sold 11,984 shares at about $7.29 ($87K), marked as a 10b5-1 plan trade. Holdings down 8% to 140,484 shares. | SEC filing Filed Oct 13, 2026, 5:01 PM ET |
| Oct 2, 2026 | Planned (10b5-1) | Peter Kaiser (Chief Development Officer) sold 9,990 shares at about $7.05 ($70K), marked as a 10b5-1 plan trade. Holdings down 4% to 254,388 shares. | SEC filing Filed Oct 6, 2026, 4:44 PM ET |
| Oct 2, 2026 | Planned (10b5-1) | Jeffrey S. Heier (Chief Scientific Officer) sold 10,869 shares at about $7.05 ($77K), marked as a 10b5-1 plan trade. Holdings down 3% to 307,457 shares. | SEC filing Filed Oct 6, 2026, 4:43 PM ET |
| Aug 31, 2026 | Sale | Donald Notman (President / COO) sold 1,099 shares at about $10.24 ($11K). Holdings down <1% to 366,529 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 2, 2026 |
| Aug 24, 2026 | Planned (10b5-1) | Peter Kaiser (Chief Development Officer) sold 3,035 shares at about $10.77 ($33K), marked as a 10b5-1 plan trade. Holdings down 1% to 264,378 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 24, 2026 | Planned (10b5-1) | Sanjay Nayak (Chief Strategy Officer) sold 1,897 shares at about $10.78 ($20K), marked as a 10b5-1 plan trade. Holdings down 1% to 326,898 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 24, 2026 | Planned (10b5-1) | Jeffrey S. Heier (Chief Scientific Officer) sold 3,296 shares at about $10.78 ($36K), marked as a 10b5-1 plan trade. Holdings down 1% to 318,326 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 24, 2026 | Planned (10b5-1) | Pravin Dugel (CEO and Director) sold 21,649 shares at about $10.77 ($233K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,525,429 shares. | SEC filing Filed Aug 26, 2026 |
| Jun 3, 2026 | Planned (10b5-1) | Nadia Waheed (Chief Medical Officer) sold 14,828 shares at about $8.27 ($123K), marked as a 10b5-1 plan trade. Holdings down 5% to 300,079 shares. | SEC filing Filed Jun 5, 2026 |
| May 26, 2026 | Planned (10b5-1) | Pravin Dugel (CEO and Director) sold 21,156 shares at about $8.20 ($173K), marked as a 10b5-1 plan trade. Holdings down 1% to 2,597,170 shares. | SEC filing Filed May 28, 2026 |
| May 26, 2026 | Planned (10b5-1) | Peter Kaiser (Chief Development Officer) sold 2,967 shares at about $8.20 ($24K), marked as a 10b5-1 plan trade. Holdings down 1% to 266,141 shares. | SEC filing Filed May 28, 2026 |
| May 26, 2026 | Planned (10b5-1) | Jeffrey S. Heier (Chief Scientific Officer) sold 3,018 shares at about $8.20 ($25K), marked as a 10b5-1 plan trade. Holdings down 1% to 320,350 shares. | SEC filing Filed May 28, 2026 |
| May 26, 2026 | Planned (10b5-1) | Sanjay Nayak (Chief Strategy Officer) sold 1,858 shares at about $8.20 ($15K), marked as a 10b5-1 plan trade. Holdings down 1% to 328,795 shares. | SEC filing Filed May 28, 2026 |
| Feb 23, 2026 | Planned (10b5-1) | Pravin Dugel (CEO and Director) sold 20,056 shares at about $8.28 ($166K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,013,022 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Planned (10b5-1) | Peter Kaiser (Chief Development Officer) sold 2,810 shares at about $8.28 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 269,108 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Planned (10b5-1) | Jeffrey S. Heier (Chief Scientific Officer) sold 3,057 shares at about $8.28 ($25K), marked as a 10b5-1 plan trade. Holdings down 1% to 323,368 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Planned (10b5-1) | Sanjay Nayak (Chief Strategy Officer) sold 1,759 shares at about $8.28 ($15K), marked as a 10b5-1 plan trade. Holdings down 1% to 330,653 shares. | SEC filing Filed Feb 25, 2026 |
| Feb 20, 2026 | Planned (10b5-1) | Nadia Waheed (Chief Medical Officer) sold 3,510 shares at about $7.74 ($27K), marked as a 10b5-1 plan trade. Holdings down 1% to 314,907 shares. | SEC filing Filed Feb 24, 2026 |
| Feb 20, 2026 | Purchase (code P) | Richard L. Md Lindstrom (Director) bought 60,229 shares at about $7.66 ($461K), reported as a purchase (code P). Holdings up 32% to 246,933 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 12, 2026 | Sale | Donald Notman (President / COO) sold 11,446 shares at about $9.04 ($103K). Holdings down 3% to 366,356 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 12, 2026 | Planned (10b5-1) | Sanjay Nayak (Chief Strategy Officer) sold 10,348 shares at about $9.04 ($94K), marked as a 10b5-1 plan trade. Holdings down 3% to 332,412 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 12, 2026 | Planned (10b5-1) | Pravin Dugel (CEO and Director) sold 124,882 shares at about $9.04 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 4% to 3,033,078 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 12, 2026 | Planned (10b5-1) | Nadia Waheed (Chief Medical Officer) sold 7,863 shares at about $9.04 ($71K), marked as a 10b5-1 plan trade. Holdings down 2% to 318,417 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 2–4, 2026 | Sale | Donald Notman (President / COO) sold 11,490 shares between Feb 2 and Feb 4 at about $8.82 ($101K). Holdings down 3% to 377,802 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 4, 2026 |
| Nov 24, 2025 | Planned (10b5-1) | Sanjay Nayak (Chief Strategy Officer) sold 1,878 shares at about $12.04 ($23K), marked as a 10b5-1 plan trade. Holdings down 1% to 277,860 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Pravin Dugel (CEO and Director) sold 19,530 shares at about $12.04 ($235K), marked as a 10b5-1 plan trade. Holdings down 1% to 3,157,960 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Peter Kaiser (Chief Development Officer) sold 3,007 shares at about $12.02 ($36K), marked as a 10b5-1 plan trade. Holdings down 2% to 191,433 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Jeffrey S. Heier (Chief Scientific Officer) sold 3,469 shares at about $12.04 ($42K), marked as a 10b5-1 plan trade. Holdings down 1% to 245,940 shares. | SEC filing Filed Nov 26, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Namrata Saroj (Chief Business Officer) sold 25,865 shares at about $10.74 ($278K), marked as a 10b5-1 plan trade. Holdings down 13% to 174,135 shares. | SEC filing Filed Nov 7, 2025 |
22 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow OCUL in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.